Physician profile
Travis Christopher Stephens
NPI 1306295894
$2,018.89
in general payments reported to CMS, 2019-2025
10 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $86.37 · 2021: $59.47 · 2022: $263 · 2023: $208 · 2024: $163 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,329.62 | 2019-2025 | Precision 1, Total30, Precision7 |
| Johnson & Johnson Vision Care, INC. | $317.07 | 2019-2025 | Acuvue |
| Apellis Pharmaceuticals, INC. | $120.10 | 2024 | Syfovre |
| Coopervision INC. | $97.18 | 2019-2025 | Misight Contact Lens |
| Glaukos Corporation | $64.21 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $23.93 | 2023 | Xiidra |
| Horizon Therapeutics Plc | $20.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.51 | 2022 | |
| Oyster Point Pharma, INC. | $15.64 | 2022 | |
| Shire North American Group INC | $14.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.